Introduction {#s1}
============

Asthma is a chronic disease that affects 21 million Americans (300 million individuals globally) and has broad implications for both the health of affected individuals and for the US economy.[@R1] The National Institutes of Health Morbidity and Mortality report indicates that as high as 15.6% of the US population may have asthma.[@R1] Furthermore, this disease is responsible for a decrease in quality of life scores,[@R5] and adult patients with asthma are twice as likely to rate their own health as 'only fair', 'poor' or 'very poor' when surveyed.[@R6]

In 2009 alone, 10.6 million physician visits[@R1] and 1.5 million emergency room (ER) visits in the USA were due to asthma.[@R7] High utilisation of asthma-related medical services, lost work and school days, and early deaths led to an estimated \$56 billion in costs.[@R8] Adults with asthma incur nearly \$2000 a year (US\$2008) in additional costs to the healthcare system compared with those without asthma.[@R3] Furthermore, a single patient with uncontrolled asthma can cost the health system up to an extra \$4423.[@R4]

Current therapies for asthma include inhaled corticosteroids (ICS), which have been hailed as 'the cornerstone of maintenance asthma therapy'.[@R10] They are the most widely used drug therapy among physicians, and when taken as prescribed can improve lung function over time.[@R11] ICS must be taken daily to provide therapeutic benefit and manage chronic symptoms.

Adherence to medication treatment plans is critical to the management of this disease. Treatment adherence of 75%--80% is considered therapeutically optimal based on evidence from studies of lung function and sputum eosinophil concentration.[@R12] One comprehensive report from Williams *et al* [@R12] determined that 24% of asthma exacerbations were attributable to ICS medication non-adherence. Further, 60% of asthma-related hospitalisations can be attributed to poor adherence.[@R10]

Currently, adherence to medications for asthma is extremely poor. The mean level of adherence for asthma medications is estimated to be 30%--40%, with a number of trials reporting adherence rates as low as 22%.[@R10] The broad range of reported adherence values and non-consensus in the literature is due, in a large part, to the challenging nature of obtaining reliable adherence metrics.[@R17] While self-reported adherence levels are the most straightforward and low cost, evidence suggests that patients over-report medication use when asked.[@R16] Other techniques for capturing adherence to medication have been used, including biometric data capture and the use of prescription refill data accessed through electronic medical records.[@R18] Each of these measures poses limitations on its own, and even taken together these metrics do not provide a clear, quantifiable measurement of adherence to daily controller ICS medications.[@R21] The need for objective real-time methods of measuring adherence to ICS medication is evident, and electronic monitoring devices (EMDs) offer a solution with potential to become the gold standard in asthma care for the 21st century.[@R22]

EMDs plus electronic text messaging (SMS) interventions have been implemented in other chronic disease states, including diabetes and congestive heart failure, with marked success.[@R23] Benefits of EMDs include the ability to track exact numbers of doses taken without a patient needing to add extra steps to their care plan, to provide new data to assist in clinical decision making, and to increase motivation and engagement in patients.[@R26] SMS or other push notifications provide study participants with feedback and/or reminders based on data captured through EMDs. In most recent years (2015--2016), evidence has been more supportive in favour of EMDs with SMS and/or push notifications. One 2016 randomised controlled trial reported significant lifts in adherence (70% intervention arm, 49% control arm) in patients using EMDs and receiving daily SMS and/or push notifications to take medications.[@R21]

While the benefits to support the use of these devices are compelling, research on the ability of EMDs to improve patient outcomes in asthma has proved to be challenging to implement, leading to inconclusive evidence on their efficacy.[@R27] Feasibility pilots have reported high rates of data transmission failure from devices,[@R30] high cost of implementation[@R17] and high rates of alert fatigue as patients are desensitised to the stimulus of message reminders.[@R31] Additionally, such technology has faced scepticism from healthcare providers. A 2016 survey of healthcare providers and members of clinical commissioning groups reported that the number 1 cited drawback to clinically administered EMD therapies was lack of research to support efficacy.[@R26]

There is a clear need to produce more data on medication adherence and clinical outcomes in populations using EMDs to determine if these promising results can be replicated. Furthermore, as EMD devices become available outside of controlled trial settings, it will be increasingly important to understand how patients interact with such technology and what barriers exist to at-home use. In order for this technology to be made widely available and cost-effective, patients must be able to set up and use the technology independently, with little oversight from research or clinical staff. Clinical trial environments do not reflect the reality of how patients would interact with such technology in a real-world environment. This study aims to contribute to that knowledge base.

The primary purpose of this virtual observational study is to measure the usability of the comprehensive Cohero Health® mHealth asthma management platform at-home including the EMD and the mobile application (BreatheSmart), which sends real-time reminders to take medication and perform mSpirometer^TM^ lung function testing. The secondary objectives of the study include monitoring real-time controller medication adherence and frequency of rescue medication use, and collecting data on asthma control, lung function, quality of life and frequency of provider visits for asthma-related adverse outcomes. Importantly, the virtual observational study design is meant to capture a more accurate snapshot of patient use of this technology in a 'real-world' setting in order to capture patient use characteristics outside of a traditional randomised controlled trial setting.

Methods and analysis {#s2}
====================

Study population {#s2a}
----------------

One hundred subjects with a self-identified diagnosis of asthma will be recruited within the USA through social media websites and ad placements online. Subjects will fill out an online screening form with the inclusion and exclusion criteria listed in [box 1](#B1){ref-type="boxed-text"}.Box 1Inclusion and exclusion criteriaInclusion criteria (all of the following):Age 18+Self-identified diagnosis of asthma for at least 6 monthsPrescribed daily inhaled corticosteroid medication for at least 3 monthsUse of a pressurised metered dose inhaler compatible with the Cohero Health mHealth HeroTracker (see online supplementary appendix A)Possesses a compatible smartphone (iOS 8.0 or higher and Android 4.3 or higher)Exclusion criteria (any of the following):Inability to provide written informed consentInability to use electronic monitoring device/mobile application platform independentlyCurrently pregnant or planning to become pregnant during the study period, as pregnancy can have an independent effect on asthma symptomsPrimary language other than English

Description of Cohero Health platform {#s2b}
-------------------------------------

### Electronic monitoring device {#s2b1}

Cohero Health HeroTrackers® are wireless Bluetooth-enabled EMDs that track medication usage using a pressure sensitive switch. They are designed for both control and rescue medications in MDI and diskus format.

### Lung function monitoring device {#s2b2}

Cohero Health mSpirometer is capable of clinical-grade lung function measurements, including peak expiratory flow and common pulmonary function test (PFT) values such as forced expiratory volume in 1 s and forced vital capacity. The device is ISO 9001 and 13 485 certified and received 510(k) clearance as a class II medical device for in-clinic use. At-home use of the mSpirometer will be assessed in this study as users will self-administer lung function testing at home with guided instruction through the BreatheSmart mobile application interface along with real-time feedback to ensure appropriate technique. The mSpirometer can be programmed for use in two modes: a 1 s peak flow measurement and a 6 s complete PFT measurement.

### Mobile application {#s2b3}

BreatheSmart is a mobile application for iOS and Android. The application uses Bluetooth to connect with the hardware components of Cohero Health's platform in order to collect adherence and lung function data and transmit data to the Cohero Health Health Insurance Portability and Accountability (HIPAA)-compliant server. BreatheSmart also sends notification reminders to remind users to take medication at times chosen by the user to align with their prescribed care plan.

Study design {#s2c}
------------

This is a 6-month virtual observational study that will occur independent of participants' normal asthma care. One hundred adults with asthma will be recruited in the USA through social media websites and ad placements online. Subjects will fill out an online screening form with the inclusion and exclusion criteria listed in [box 1](#B1){ref-type="boxed-text"}. If deemed eligible on the online self-screening form, they will be contacted by the study team to further discuss the study and conduct the informed consent process via an online web portal. The participants' attention is specifically called to the portion of the consent form that indicated that this study does not replace normal care by a licensed provider, and that this study is an observation of use of EMDs, and not a treatment study in any way.

Study participants will be asked to attend regular visits with their care providers and continue to take their asthma medication as recommended by their clinician. Once they are enrolled in the study, patients will be randomised to one of two arms and follow the study design outlined in [figure 1](#F1){ref-type="fig"}. Fifty participants will be placed in group A and receive the mSpirometer programmed for 6 s complete PFT testing and 50 participants will be placed in group B and receive the mSpirometer programmed for 1 s peak flow measurement in order to assess patient experiences with each version of the technology.

![CONSORT flow diagram. PFT, pulmonary function test.](bmjresp-2017-000204f01){#F1}

Once enrolled and randomised in the study, participants will be shipped a device package including EMDs for control and rescue inhalers as well as an mSpirometer. Devices will be accompanied by user manuals with detailed instructions for research participants to download the BreatheSmart application to their mobile device and to set up EMDs on their own. Users who are unable to set up the mobile application and devices on their own will be offered optional interactive phone or video conference assistance from the research team.

As part of the virtual baseline visits, participants will complete an online form of the Asthma Control Test (ACT), EuroQol-5D validated quality of life questionnaire, baseline asthma disease and demographic questionnaire, as well as instructed to perform lung function testing using the mSpirometer.

Throughout the study, group A will receive reminders from the mobile app to perform monthly 6 s PFT testing on the mSpirometer and group B will receive reminders to perform a weekly 1 s peak flow testing on the mSpirometer. Both groups will also receive daily reminders from the mobile app to take their medication and will be able to monitor their own medication usage on a daily and weekly basis.

Study participants will also be asked to fill out questionnaires online at 3 months and 6 months (including ACT and EuroQol-5D). At the end of the study, participants will be invited to end-of-study focus groups in a virtual text chat room.

Study enrolment is planned to start in March 2017 and the final patient is planned to finish in March 2018.

Outcomes {#s2d}
--------

### Primary study endpoint {#s2d1}

Usability is measured by:backend measures of subjects' use of the EMD and mobile app and ability of platform to sync and upload datausability questionnaireacceptability questionnaire including subjects' opinion of the platform and its featuresvirtual focus groups with study subjects.

### Important secondary objectives {#s2d2}

Outcome measures include:real-time controller medication adherencefrequency of rescue medication use as measured by the EMDsasthma controllung functionquality of life using the EuroQol-5Dhealthcare utilisation during the study period.

Measurements {#s2e}
------------

Patient usage and interaction with the mobile app as well as timing and frequency of controller and rescue medication use will be measured daily during the study period. Additionally, per the study design described above, patients will be prompted to perform regular lung function measurements during the study period (monthly 6 s PFT for group A, weekly 1 s peak flow for group B).

Questionnaires {#s2f}
--------------

Asthma control will be measured by the ACT at baseline, 3 months and 6 months. Quality of life during the study period will be assessed using the EuroQol-5D. Self-reported healthcare utilisation including provider visits for asthma-related adverse outcomes will be assessed by questionnaire. Self-reported asthma exacerbations including ER visits, hospitalisations or systemic corticosteroid therapy will also be assessed for this period.

Statistical methods and data analysis plan {#s2g}
------------------------------------------

### Logistics {#s2g1}

Backend measures of usability are also recorded and uploaded into the Structured Query Language (SQL) database. Analysis will be performed by the research team at Cohero Health. All analyses will be based on an intention-to-treat.

Simple paired t-test will be used to assess for significant change in ACT, quality of life and lung function. Lung function metrics will be aggregated across the study period to look for population trends. Other baseline and follow-up survey findings, including adverse asthma events, will be assessed for change from baseline to follow-up.

### Sample size {#s2g2}

This is a cohort observational study in which we aim to assess the usability of the Cohero Health mobile platform for at-home patient use as an asthma self-management tool. As the primary outcome cannot be boiled down to a single quantitative measure, we were not able to perform appropriate sample size calculation for the primary objective. However, with 100 patients for 6 months, we will be obtaining, if it is assumed an average patient takes two medication puffs per day, 2×30×6=up to 360 real-time medication measurements during the study period per patient.

### Data collection {#s2g3}

Research survey responses will be input directly by study subjects into the BreatheSmart mobile application where they are saved into a backend SQL database. Medication adherence data are recorded on the EMD, which then transmits[Supplementary file 1](#SP1){ref-type="supplementary-material"} that information via Bluetooth Low Energy to the mobile app and up to our HIPAA-compliant server and backend SQL database. The lung function data are recorded directly by the mSpirometer and also sent via Bluetooth Low Energy  to the mobile app and again to the SQL database.
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### Data monitoring and quality assurance {#s2g4}

Prior to study enrolment, all research staff will be trained in principles of human subject's protection and maintenance of confidentiality of participant data. This study will be monitored by a representative of Cohero Health. Routine interim monitoring of the data will be conducted every quarter with two audits to be conducted between each quarter. Monitoring will be in the form of a review of the data recorded in the BreatheSmart applications. Any issues identified will be communicated to the investigator. The investigator is expected to resolve any outstanding action items in a timely manner.

Discussion {#s3}
==========

This study aims to assess the use of an EMD and asthma management system in a deployment consistent with the intended use of such technologies. By using a virtual study design without traditional in-person study visits, we intend to emulate the real-world scenario in which patients might interact with the technology and to demonstrate the ability of EMDs to engage patients, sustain engagement and assess usability of these products with minimal research staff support. Thus we seek to reliably and objectively validate EMD as a method for adherence measurement. As this study is being conducted by Cohero Health, which designs the EMD and asthma management platform being assessed, we hope the virtual study design will in particular minimise potential bias by having fewer interactions between the study team and study participants, as well as by minimising Hawthorne effect, which may induce patients to be more adherent because they are aware they are being observed. We aim to be as inclusive as possible by not imposing restrictions on location, quality of phones, access to Wi-Fi and phone data plans, socioeconomic status, and technological proficiency.

If Cohero Health mobile technology proves easy to use at home, it will validate this technology as a cost-effective solution to improve medication adherence and outcomes in patients with asthma using daily ICS. If there prove to be challenges in the implementation of the study related to such a 'hands-off' approach, it will enable technology and usability optimisation to improve this product for patient use based on the direct feedback of study participants and thus lead to patient-centred improvements in the design of this technology. The use of an electronic recruitment strategy means that we anticipate a more diverse patient population as it is not limited to those patients in a specific zip code or seen at a specific health centre. Thus, we anticipate findings will be more broadly applicable to the general asthma patient population in the USA. This study will be an important stepping stone for future endeavours to provide evidence of the cost-effectiveness that would be invaluable for providers and payers in considering this approach for daily clinical practice.
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